Clinical trials in gynecological cancer

被引：5

作者：

Trimble, E. L.

Davis, J.

Disaia, P.

Fujiwara, K.

Gaffney, D.

Kristensen, G.

Ledermann, J.

Pfisterer, J.

Quinn, M.

Reed, N.

Schoenfeldt, M.

Thigpen, J. T.

机构：

[1] NCI, Cancer Therapy Evaluat Program, Bethesda, MD 20892 USA

[2] N Glasgow Univ Hosp NHS Trust, Glasgow, Lanark, Scotland

[3] Univ Calif Irvine, Med Ctr, Irvine, CA 92717 USA

[4] Saitama Med Univ, Urawa, Saitama, Japan

[5] Univ Utah, Huntsman Canc Hosp, Salt Lake City, UT 84112 USA

[6] Norwegian Radium Hosp, Oslo, Norway

[7] Canc Res UK, London, England

[8] UCL Canc Trials Ctr, London, England

[9] Univ Klinikum Schleswig Holstein, Lubeck, Germany

[10] Univ Melbourne, Parkville, Vic 3052, Australia

[11] Beatson Oncol Ctr, Glasgow, Lanark, Scotland

[12] EMMES Corp, Rockville, MD USA

[13] Univ Mississippi, Sch Med, University, MS 38677 USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2007年 / 17卷 / 03期

关键词：

gynecologic cancer; ovarian cancer; cervical cancer; endometrial cancer; clinical trials; GCIG;

D O I：

10.1111/j.1525-1438.2007.00667.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The Gynecologic Cancer Intergroup is comprised representatives from international gynecological cancer trials organizations, which collaborate in multicenter studies to answer the clinical challenges in gynecological cancer. This review article highlights the key clinical questions facing clinical trialists over the next decade, the information and infrastructure resources available for trials, and the methods of trial development. We cover human papillomavirus (HPV)-associated neoplasia, including cervical cancer, together with endometrial cancer, ovarian cancer, and vulvar cancer. Infrastructure for clinical trials includes a database for trials, templates for protocol development, patient educational material, and financial support for clinical trials. Other critical issues include support from government and charities and government regulations.

引用

页码：547 / 556

页数：10

共 51 条

[1] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].